AI assistant
Marker Therapeutics, Inc. — Director's Dealing 2018
Oct 10, 2018
35150_dirs_2018-10-10_aa2f8833-49e9-4566-bb25-1525ca7ea5f2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TAPIMMUNE INC. (TPIV)
CIK: 0001094038
Period of Report: 2018-10-09
Reporting Person: WILSON GLYNN (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-10-09 | Common Stock | A | 31120 | — | Acquired | 189337 | Direct |
| 2018-10-09 | Common Stock | F | 7561 | — | Disposed | 181776 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-10-09 | Employee Employment Agreement (right to receive) | $ | M | 31120 | Disposed | Common Stock (31120) | Direct |
Footnotes
F1: Represents issuance of fully vested shares of common stock under the Company's 2014 Omnibus Stock Ownership Plan pursuant to the Company's obligation to do so under the terms of the Reporting Person's employment agreement as amended.
F2: Represents withholding of shares of common stock to satisfy tax withholding obligations in connection with the issuance of the stock award.
F3: Represents elimination of Reporting Person's right to receive shares under his employment agreement following the issuance of the shares to the Reporting Person reflected on Table I by the Company.